MOSAIC
MidOStaurin + Gemtuzumab OzogAmIcin Combination in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
| Studienleiter | Prof. Dr. Christoph Röllig |
|---|---|
| EudraCT-Nr. | 2019-003863-23 |
| Studientyp | randomisiert, Phase I / II |
| Indikation | AML |
| ClinicalTrial | NCT04385290 |